cafusertib + cytarabine

Text_start**Cafusertib + cytarabine** is an investigational combination therapy under clinical evaluation for the treatment of acute myeloid leukemia (AML). Cafusertib (also known as AZD5363) is an oral and intravenous pan-AKT inhibitor, targeting the protein kinase B (AKT) pathway, which is involved in cell proliferation and survival. Cytarabine (also known as ara-C) is an antimetabolite and DNA synthesis inhibitor widely used in the treatment of hematologic malignancies such as AML. The combination aims to exploit potential drug synergy in AML, particularly in relapsed or refractory patients. The primary clinical study for this combination is a phase 1 trial evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of cafusertib in combination with low-dose cytarabine in AML patients not eligible for intensive therapy[1][2][5][7].Text_end

Other names

cafusertib hydrochloride + cytarabineAZD5363 + cytarabineara-C + cafusertib